|
Abstract To explore the clinical efficacy of estradiol valerate combined with pelvic floor rehabilitation for treating patients with pelvic floor dysfunction. Methods: 92 patients with pelvic floor dysfunction were divided into study group and control group randomly. The patients in control group were treated by pelvic floor rehabilitation, and the patients in study group were treated by oral estradiol valerate (1mg/d) combined with pelvic floor rehabilitation. The left and right anal fissure diameter, anterior and posterior diameter and area (LHLP, LHAP and LHA), and the pelvic floor muscle strength of patients in the two groups were measured by the perineum threedimensional ultrasound and compared between before and after treatment. The pelvic floor dysfunction questionnaire (PFIQ-7) was used to assess the change of the pelvic floor function of patients. Sexual quality of life questionnaire (PISQ-12) was used to assess the sexual life quality of patients. Results: After treatment, LHLP, LHAP and LHA of patients in both groups at rest, anal contraction and Valsalva action were significantly decreased (P<0.05), and LHLP, LHAP and LHA of patients in study group were significant lower than those of patients in control group (P<0.05). The pelvic floor muscle strength of patients in both groups was improved significantly after treatment (P<0.05), and the pelvic floor muscle strength improvement of patients in study group was significant better than that of patients in control group (P<0.05). The PISQ-12 scores of patients in both groups increased significantly after treatment, and the PISQ-12 scores of patients in study group was significant higher than that of patients in control group (P<0.05). The PFIQ-7 scores of patients in both groups was decreased significantly, and the PFIQ-7 score was significant lower than that of patients in control group (P<0.05). Conclusion: Estradiol valerate can further improve the clinical efficacy of patients with pelvic floor dysfunction.
|
|
|
|
|
|
